甲氨蝶呤联合泼尼松10mg策略在早期类风湿关节炎的长期结局更优
基于第二项Computer-Assisted Management in Early Rheumatoid Arthritis试验的后续随访,比较初始甲氨蝶呤联合泼尼松10mg(MTX+pred)与联合安慰剂(MTX+plac)策略的长期结局。结果显示, former MTX+pred组启动首个bDMARD的比例更低(31% vs 50%,p=0.003),试验后2年随访时侵蚀评分中位数更低(0 vs 0,p=0.002),且未增加GC相关合并症。
要点
- 初始MTX+泼尼松10mg策略较MTX+安慰剂显著降低首个bDMARD启动率(31% vs 50%,p=0.003)。
- 试验后2年随访时,former MTX+pred组侵蚀评分中位数显著更低(0 vs 0,p=0.002)。
- 后续随访期间两组GC相关合并症发生无显著差异。
核心结论
- 在早期类风湿关节炎中,MTX为基础的治疗策略加用泼尼松10mg/日可降低首个bDMARD启动率并显著改善影像学结局,且不增加GC相关合并症。
研究设计与样本
- 基于第二项Computer-Assisted Management in Early Rheumatoid Arthritis试验的后续随访,回顾性收集泼尼松和bDMARD使用及GC相关合并症发生数据,采用Sharp/van der Heijde评分,使用Fisher精确检验和Mann-Whitney U检验分析。
主要发现
- 218例患者有试验后随访数据,最长随访时间11.8年。
- former MTX+pred组较former MTX+plac组启动首个bDMARD的患者更少:31% vs 50%,p=0.003。
- 试验后2年随访时,former MTX+pred组较former MTX+plac组侵蚀评分中位数显著更低:0(范围0-0) vs 0(0-2),p=0.002。
- 试验后随访期间,former策略组间GC相关合并症发生无显著差异。
临床怎么用
- 对于早期类风湿关节炎,可考虑在MTX基础上加用泼尼松10mg/日作为初始治疗策略,以改善长期影像学结局并减少bDMARD启动。
- 在后续随访中,按试验方案尽可能逐渐减停泼尼松,并监测GC相关合并症。
局限性
- 试验后随访数据为回顾性收集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In the second Computer-Assisted Management in Early Rheumatoid Arthritis trial, patients had started with methotrexate and 10 mg prednisone (MTX+pred) or placebo (MTX+plac). After the trial, prednisone was tapered and stopped, if possible. The objective was to compare, during the post-trial follow-up between the two former strategy groups, initiation of the first biological disease-modifying antirheumatic drug (bDMARD), radiographic outcome and onset of glucocorticoid (GC)-related comorbidities. METHODS: Data on prednisone and bDMARD use and onset of GC-related comorbidities were collected retrospectively. Sharp/van der Heijde scoring was performed. Data were analysed using Fisher's exact and Mann-Whitney U tests. RESULTS: Of 218 patients post-trial follow-up data were available. The maximum follow-up time was 11.8 years. Fewer patients initiated a first bDMARD in the former MTX+pred compared with the former MTX+plac strategy group: 31% vs 50%, p=0.003. At the 2 year post-trial follow-up, the median erosion score was significantly lower in the former MTX+pred versus former MTX+plac strategy group: 0 (range 0-0) versus 0 (0-2), p=0.002. No significant differences between the former strategy groups in the onset of GC-related comorbidities during the post-trial follow-up were found. CONCLUSION: Addition of 10 mg prednisone daily to an MTX-based treatment strategy in early rheumatoid arthritis results in a lower initiation rate of a first bDMARD and significantly better radiographic outcomes, yet does not result in more GC-related comorbidities.
引用
- Safy M, Jacobs J, IJff ND, et al. Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial. Ann Rheum Dis. 2017. PMID: 28450312. doi:10.1136/annrheumdis-2016-210647
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。